Phase 3 trial results released by Protagonist Therapeutics has revealed that icotrokinra, an oral IL-23 receptor inhibitor, achieved clear or nearly clear skin in 66% of patients with ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update ...

Johnson & Johnson (J&J) and Protagonist Therapeutics’ investigational oral peptide icotrokinra (JNJ-2113) has been associated ...

The primary endpoint was met, with 57% of subjects treated with the therapy achieving clear or almost clear skin.

J&J announces positive data from phase 3 ICONIC-TOTALa study of icotrokinra to treat scalp and genital psoriasis: Spring House, Pennsylvania Monday, May 12, 2025, 11:00 Hrs [IST] ...

House: Johnson & Johnson has announced new data from the Phase 3 ICONIC-TOTAL study investigating icotrokinra (JNJ-2113), the ...

She loves testing health products, like sports bras and foot spas, and hitting snooze on her alarm. If you’ve ever had a professional pedicure, you know the indulgent delight they bring ...

of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin ...

1 Gooderham, M.J. et al. Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that ...

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16Icotrokinra continues to ...